Compare Ginkgo Bioworks Holdings Inc (DNA) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Orion Office REIT Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.41 (market cap $505.73M), while Orion Office REIT Inc trades at $2.75 (market cap $158.01M). The key difference: Ginkgo Bioworks Holdings Inc is far larger — about 3.2× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 2.89% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | ONL | |
|---|---|---|
Market Cap | $505.73M | $158.01M |
Sector | Health | Real Estate |
52-Week High | $16.14 | $3.04 |
52-Week Low | $5.48 | $1.93 |
Enterprise Value | $607.68M | $574.95M |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
ONL trades at $2.80, up 1.82% with a bullish technical signal. The company reported mixed Q2 2026 results with an EPS beat but faces fundamental challenges including declining revenue and negative net income margins. Analyst consensus is split 50/50 between Buy and Hold ratings. Recent news highlights strategic review progress and portfolio repositioning efforts.
Outlook remains cautious due to persistent losses and revenue decline, though low P/B ratio and dividend payments offer some value. Key risks include continued negative profitability and high debt levels. The stock presents speculative value for investors tolerant of turnaround execution risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
